Estimates Revisions Avalo Therapeutics, Inc.
Stocks
AVTX
US05338F3064
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.37 USD | +8.33% |
|
+0.83% | +6.66% |
| 12:26am | Avalo Therapeutics Says Some Shareholders May Sell Up to 128,189 Shares | MT |
| 07-05 | Certain Common Stock of Avalo Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 5-JUL-2026. | CI |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AVTX Stock
- Consensus Avalo Therapeutics, Inc.
- Estimates Revisions
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
